Table 2.
Model 1* | Model 2** | Model 3*** | |||||||
n | events | HR (95% C.I.) | p-value | HR (95% C.I.) | p-value | HR (95% C.I.) | p-value | p for trend | |
Time to first recurrence | |||||||||
250–850 mL | 205 | 64 | ref | ref | ref | 0.86 | |||
850–1200 mL | 257 | 98 | 1.24 (0.90–1.69) | 0.19 | 1.26 (0.92–1.72) | 0.16 | 1.17 (0.85–1.62) | 0.33 | |
>1200 mL | 254 | 76 | 0.92 (0.66–1.28) | 0.62 | 0.93 (0.67–1.31) | 0.70 | 0.98 (0.70–1.38) | 0.91 | |
Time to multiple recurrences | |||||||||
250–850 mL | 205 | 92 | ref | ref | ref | 0.78 | |||
850 –1200 mL | 257 | 171 | 0.95 (0.83–1.09) | 0.48 | 0.96 (0.84–1.10) | 0.57 | 0.95 (0.83–1.08) | 0.42 | |
>1200 mL | 254 | 115 | 1.05 (0.90–1.22) | 0.51 | 1.05 (0.90–1.23) | 0.54 | 1.01 (0.87–1.19) | 0.85 |
*Model 1 is unadjusted, **Model 2 is adjusted for age, sex, and smoking status, ***Model 3 is adjusted for age, sex, smoking status, tumour stage, grade, size and multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the variable re-resection of a bladder tumour (second transurethral resection).